Stayble's CEO to BioStock: "We are looking forward to new study results in 2024"

Stayble Therapeutics enters the new year with focus on the phase Ib study in disc herniation. Patient recruitment is ongoing at four clinics and the company's plan is to be able to present study results in 2024, without additional funding. CEO Andreas Gerward tells us more in an interview. 

Read the full article at biostock.se:

https://www.biostock.se/en/2024/01/staybles-ceo-we-are-looking-forward-to-new-study-results-in-2024/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se